Plotkin Financial Advisors’s ProShares Ultra Health Care RXL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-12,884
Closed -$589K – 94
2023
Q4
$589K Sell
12,884
-1,922
-13% -$80.4K 0.45% 35
2023
Q3
$612K Sell
14,806
-5,668
-28% -$250K 0.54% 30
2023
Q2
$912K Buy
20,474
+1,012
+5% +$44.5K 0.76% 27
2023
Q1
$832K Buy
19,462
+364
+2% +$15.9K 0.77% 26
2022
Q4
$903K Sell
19,098
-12
-0.1% -$544 0.92% 25
2022
Q3
$737K Buy
19,110
+834
+5% +$36.8K 0.75% 27
2022
Q2
$797K Buy
18,276
+2,200
+14% +$101K 0.76% 27
2022
Q1
$823K Buy
16,076
+2,282
+17% +$110K 0.57% 30
2021
Q4
$772K Buy
+13,794
New +$699K 0.49% 36

Other funds holding RXL

Plotkin Financial Advisors's RXL Position: Q1 2024 in Review

Plotkin Financial Advisors sold out of ProShares Ultra Health Care (RXL) in Q1 2024, closing a stake of 12,884 shares — an estimated $589K sold.

Plotkin Financial Advisors first reported a position in RXL in Q4 2021 and held it in 9 quarters. The position peaked at $912K in Q2 2023. 17 funds tracked by Wall St. Rank hold RXL as of Q1 2024.

  • Plotkin Financial Advisors reported no remaining ProShares Ultra Health Care position as of Q1 2024 after selling out during the quarter.
  • Plotkin Financial Advisors sold 12,884 ProShares Ultra Health Care shares in Q1 2024, an estimated $589K.
  • Plotkin Financial Advisors first reported a position in ProShares Ultra Health Care in Q4 2021 and held it in 9 quarters.
  • Plotkin Financial Advisors's ProShares Ultra Health Care position peaked at $912K in Q2 2023.
  • 17 funds tracked by Wall St. Rank held ProShares Ultra Health Care as of Q1 2024.

Based on Plotkin Financial Advisors's 13F filing for Q1 2024, filed 15 Nov 2024.